参与物
| 角色 | 名称 | HCID | 投料 |
|---|
| 反应物 | 4-苄氧基溴苯 | HCID 138835 | — |
| 反应物 | (R)-4-Boc-2-甲基哌嗪 | HCID 2756811 | — |
| 试剂 | 叔丁醇钾 | HCID 23665647 | — |
| 催化剂 | 三叔丁基膦 | HCID 83681 | — |
| 催化剂 | 二(三叔丁基膦)钯 | HCID 2734558 | — |
| 溶剂 | 四氢呋喃 | HCID 8028 | — |
| 产物 | (R)-4-(4-benzyloxyphenyl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester | HCID 70873375 | 35.73% |
反应步骤
A mixture of 1-(benzyloxy)-4-bromobenzene (158 mg, 0.60 mmol), (R)-tert-butyl 3-methylpiperazine-1-carboxylate (60.1 mg, 0.3 mmol), bis(tri-t- butylphosphine)palladium(0) (15.33 mg, 0.03 mmol) and potassium tert-butoxide (37.0 mg, 0.33 mmol) in THF (2 mL) was flushed with nitrogen and sealed into a microwave tube. The reaction was heated to 150 °C for 20 minutes in the microwave reactor and cooled to RT. The reaction mixture was filtered and the filtrate evaporated to dryness. The residue was dissolved in MeOH (5mL) and purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 0.35M NH3/MeOH and pure fractions were evaporated to dryness. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford (R)-tert-butyl 4-(4-(benzyloxy)phenyl)-3-methylpiperazine-1-carboxylate (41.0 mg, 35.7 %) as a colourless oil that solidified on standing.
来源与证据
| 来源数据集 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-8459652e6963448495d966b232514570 |
|---|
| 来源说明 | 750 AstraZeneca ELN dataset |
|---|